These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18549870)
1. Lipoprotein-associated phospholipase A2 and risk of stroke. Gorelick PB Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870 [TBL] [Abstract][Full Text] [Related]
2. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA; Jones PH; Davidson MH Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Anderson JL Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868 [TBL] [Abstract][Full Text] [Related]
4. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022 [TBL] [Abstract][Full Text] [Related]
10. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease. Epps KC; Wilensky RL J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587 [TBL] [Abstract][Full Text] [Related]
11. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Carlquist JF; Muhlestein JB; Anderson JL Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360 [TBL] [Abstract][Full Text] [Related]
13. Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction. Cojocaru IM; Cojocaru M; Tănăsescu R; Iliescu I; Dumitrescu L; Burcin C; Gurban CV; Sfrijan F Rom J Intern Med; 2009; 47(1):61-5. PubMed ID: 19886071 [TBL] [Abstract][Full Text] [Related]
14. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Noto H; Chitkara P; Raskin P J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Lerman A; McConnell JP Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867 [TBL] [Abstract][Full Text] [Related]
16. Identifying the vulnerable patient with rupture-prone plaque. Weintraub HS Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869 [TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Khakpour H; Frishman WH Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473 [TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Delgado P; Chacón P; Penalba A; Pelegri D; García-Berrocoso T; Giralt D; Santamarina E; Ribó M; Maisterra O; Alvarez-Sabín J; Rosell A; Montaner J Cerebrovasc Dis; 2012; 33(2):150-8. PubMed ID: 22178747 [TBL] [Abstract][Full Text] [Related]
19. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Toth PP; McCullough PA; Wegner MS; Colley KJ Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]